MindWalk Holdings Corp. (HYFT)
NASDAQ: HYFT · Real-Time Price · USD
2.190
+0.030 (1.39%)
At close: Jan 27, 2026, 4:00 PM EST
2.160
-0.030 (-1.37%)
After-hours: Jan 27, 2026, 6:39 PM EST
MindWalk Holdings Revenue
MindWalk Holdings had revenue of 4.12M CAD in the quarter ending October 31, 2025, with 53.94% growth. This brings the company's revenue in the last twelve months to 26.65M, up 49.46% year-over-year. In the fiscal year ending April 30, 2025, MindWalk Holdings had annual revenue of 24.52M with 0.01% growth.
Revenue (ttm)
26.65M CAD
Revenue Growth
+49.46%
P/S Ratio
4.84
Revenue / Employee
261,304 CAD
Employees
102
Market Cap
102.25M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 24.52M | 2.00K | 0.01% |
| Apr 30, 2024 | 24.52M | 3.85M | 18.65% |
| Apr 30, 2023 | 20.67M | 1.30M | 6.72% |
| Apr 30, 2022 | 19.36M | 1.45M | 8.11% |
| Apr 30, 2021 | 17.91M | 3.85M | 27.41% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 58.42M |
| Korro Bio | 7.37M |
| Coya Therapeutics | 3.99M |
| Cibus | 3.79M |
| Pyxis Oncology | 2.82M |
| Precision BioSciences | 698.00K |
| Inovio Pharmaceuticals | 182.34K |
HYFT News
- 19 hours ago - MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics - Business Wire
- 13 days ago - MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease - Business Wire
- 15 days ago - REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight - Business Wire
- 17 days ago - MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight - Business Wire
- 6 weeks ago - MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline - Business Wire
- 7 weeks ago - MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025 - Business Wire
- 2 months ago - MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025 - Business Wire